{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,9]],"date-time":"2026-09-09T20:03:54Z","timestamp":1788984234683,"version":"build-2803163510"},"reference-count":24,"publisher":"BMJ","issue":"4","license":[{"start":{"date-parts":[[2024,11,23]],"date-time":"2024-11-23T00:00:00Z","timestamp":1732320000000},"content-version":"unspecified","delay-in-days":22,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100000265","name":"Medical Research Council","doi-asserted-by":"publisher","award":["G0800629"],"award-info":[{"award-number":["G0800629"]}],"id":[{"id":"10.13039\/501100000265","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100000265","name":"Medical Research Council","doi-asserted-by":"publisher","award":["MR\/J002720\/1"],"award-info":[{"award-number":["MR\/J002720\/1"]}],"id":[{"id":"10.13039\/501100000265","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100003776","name":"Newcastle upon Tyne Hospitals NHS Trust","doi-asserted-by":"crossref","id":[{"id":"10.13039\/501100003776","id-type":"DOI","asserted-by":"crossref"}]},{"name":"European Union Horizon 2020 research and innovation program"},{"name":"NIHR Biomedical Research Centre at Newcastle University"},{"DOI":"10.13039\/501100014034","name":"Foundation for Research in Rheumatology","doi-asserted-by":"publisher","award":["Grant agreement No 806975"],"award-info":[{"award-number":["Grant agreement No 806975"]}],"id":[{"id":"10.13039\/501100014034","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100013322","name":"European Federation of Pharmaceutical Industries and Associations","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100013322","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["bmj.com"],"crossmark-restriction":true},"short-container-title":["RMD Open"],"accepted":{"date-parts":[[2024,11,6]]},"published-print":{"date-parts":[[2024,11]]},"abstract":"<jats:sec>\n                    <jats:title>Objectives<\/jats:title>\n                    <jats:p>The Newcastle Sjogren\u2019s Stratification Tool (NSST) stratifies Sjogren\u2019s disease patients into four subtypes. Understanding the stability of the subtypes is vital if symptom-based stratification is to be more broadly adopted. In this study, we stratify patients longitudinally to understand how symptom-based subtypes vary over time and factors influencing subtype change.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>274 patients from the United Kingdom Primary Sj\u00f6gren\u2019s Syndrome Registry (UKPSSR) with data permitting NSST subtype assignment from two study visits were included. The French Assessment of Systemic Signs and Evolution of Sjogren\u2019s Syndrome (ASSESS) cohort (n=237) acted as an independent comparator. Group analyses of significant differences were performed, with logistic regression models used to assess covariates of subtype stability.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>UKPSSR and ASSESS cohorts showed a broadly similar proportion of subjects in each subtype and similar baseline clinical characteristics except body mass index (BMI). Several baseline characteristics differ significantly between the subtypes, most notably anti-Ro status and BMI. Subtype membership was reasonably stable in both cohorts with 60% and 57% retaining subtype. The high-symptom burden subtype was the most stable over time with 70% and 67% retaining subtype. Higher baseline probability score was the greatest predictor of subtype stability with higher C4 levels, antidepressant use, and a higher CCI score also predicting increased stability.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>NSST subtype membership remains stable over time in a large proportion of patients. When subtype transition is associated with factors at baseline, it is most strongly associated with an uncertain subtype allocation. Our findings support the hypothesis that symptom-based subtypes reflect genuine pathobiological endotypes and therefore maybe important to consider in trial design and clinical management.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1136\/rmdopen-2024-004914","type":"journal-article","created":{"date-parts":[[2024,11,24]],"date-time":"2024-11-24T13:05:26Z","timestamp":1732453526000},"page":"e004914","update-policy":"https:\/\/doi.org\/10.1136\/crossmarkpolicy","source":"Crossref","is-referenced-by-count":5,"title":["Stability of symptom-based subtypes in Sjogren\u2019s disease"],"prefix":"10.1136","volume":"10","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-4238-8651","authenticated-orcid":false,"given":"Joe Scott","family":"Berry","sequence":"first","affiliation":[{"name":"Translational and Clinical Research Institute, Newcastle University, Newcastle upon Tyne, Tyne and Wear, UK"},{"name":"Clinical and Translational Medicine Research Centre, University of Sunderland, Sunderland, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0083-8543","authenticated-orcid":false,"given":"Jessica","family":"Tarn","sequence":"additional","affiliation":[{"name":"Translational and Clinical Research Institute, Newcastle University, Newcastle upon Tyne, Tyne and Wear, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John","family":"Casement","sequence":"additional","affiliation":[{"name":"Bioinformatics Support Unit, Newcastle University, Newcastle upon Tyne, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dennis","family":"Lendrem","sequence":"additional","affiliation":[{"name":"Translational and Clinical Research Institute, Newcastle University, Newcastle upon Tyne, Tyne and Wear, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kyle","family":"Thompson","sequence":"additional","affiliation":[{"name":"Translational and Clinical Research Institute, Newcastle University, Newcastle upon Tyne, Tyne and Wear, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4244-5417","authenticated-orcid":false,"given":"Xavier","family":"Mariette","sequence":"additional","affiliation":[{"name":"Rheumatology, Assistance Publique-H\u00f4pitaux de Paris (AP-HP), H\u00f4pitaux universitaires Paris-Sud \u2013 H\u00f4pital Bic\u00eatre, Le Kremlin Bic\u00eatre, France"},{"name":"Universit\u00e9 Paris-Sud, Center for Immunology of Viral Infections and Auto-immune Diseases (IMVA), Institut pour la Sant\u00e9 et la Recherche M\u00e9dicale (INSERM) UMR 1184, Universit\u00e9 Paris-Saclay, Le Kremlin Bic\u00eatre, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9469-946X","authenticated-orcid":false,"given":"Jacques-Eric","family":"Gottenberg","sequence":"additional","affiliation":[{"name":"Rheumatology, Hopitaux universitaires de Strasbourg, Strasbourg, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wan-Fai","family":"Ng","sequence":"additional","affiliation":[{"name":"Translational and Clinical Research Institute, Newcastle University, Newcastle upon Tyne, Tyne and Wear, UK"},{"name":"HRB Clinical Research Facility, University College Cork, Cork, Ireland"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"239","published-online":{"date-parts":[[2024,11,24]]},"reference":[{"key":"2025090313283870000_10.4.e004914.1","first-page":"498","volume-title":"Sj\u00f6gren\u2019s Disease: A New Era for Clinical Trials","volume":"404","author":"Colafrancesco","year":"2024"},{"key":"2025090313283870000_10.4.e004914.2","doi-asserted-by":"crossref","first-page":"e85","DOI":"10.1016\/S2665-9913(19)30042-6","article-title":"Symptom-based stratification of patients with primary Sj\u00f6gren\u2019s syndrome: multi-dimensional characterisation of international observational cohorts and reanalyses of randomised clinical trials","volume":"1","author":"Tarn","year":"2019","journal-title":"Lancet Rheumatol"},{"key":"2025090313283870000_10.4.e004914.3","doi-asserted-by":"crossref","first-page":"1593","DOI":"10.1007\/s00296-021-04927-y","article-title":"Revisiting the JOQUER trial: stratification of primary Sj\u00f6gren\u2019s syndrome and the clinical and interferon response to hydroxychloroquine","volume":"41","author":"Collins","year":"2021","journal-title":"Rheumatol Int"},{"key":"2025090313283870000_10.4.e004914.4","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-021-23472-7"},{"key":"2025090313283870000_10.4.e004914.5","doi-asserted-by":"crossref","first-page":"394","DOI":"10.1186\/s12967-021-03051-6","article-title":"Longitudinal analysis of symptom-based clustering in patients with primary Sjogren\u2019s syndrome: a prospective cohort study with a 5-year follow-up period","volume":"19","author":"Lee","year":"2021","journal-title":"J Transl Med"},{"key":"2025090313283870000_10.4.e004914.6","doi-asserted-by":"crossref","first-page":"1569","DOI":"10.1002\/art.42238","article-title":"Symptom-Based Cluster Analysis Categorizes Sj\u00f6gren\u2019s Disease Subtypes: An International Cohort Study Highlighting Disease Severity and Treatment Discordance","volume":"74","author":"McCoy","year":"2022","journal-title":"Arthritis Rheumatol"},{"key":"2025090313283870000_10.4.e004914.7","first-page":"34","volume-title":"What Can Patients Tell Us in Sj\u00f6gren\u2019s Syndrome","volume":"5","author":"Berry","year":"2024"},{"key":"2025090313283870000_10.4.e004914.8","doi-asserted-by":"crossref","first-page":"e553","DOI":"10.1016\/S2665-9913(21)00122-3","article-title":"Composite of Relevant Endpoints for Sj\u00f6gren\u2019s Syndrome (CRESS): development and validation of a novel outcome measure","volume":"3","author":"Arends","year":"2021","journal-title":"Lancet Rheumatol"},{"key":"2025090313283870000_10.4.e004914.9","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2021-222054"},{"key":"2025090313283870000_10.4.e004914.10","doi-asserted-by":"crossref","first-page":"e216","DOI":"10.1016\/S2665-9913(23)00340-5","article-title":"Identification of distinct subgroups of Sj\u00f6gren\u2019s disease by cluster analysis based on clinical and biological manifestations: data from the cross-sectional Paris-Saclay and the prospective ASSESS cohorts","volume":"6","author":"Nguyen","year":"2024","journal-title":"Lancet Rheumatol"},{"key":"2025090313283870000_10.4.e004914.11","doi-asserted-by":"crossref","first-page":"540","DOI":"10.1016\/S0140-6736(24)01211-X","article-title":"Safety and efficacy of subcutaneous iscalimab (CFZ533) in two distinct populations of patients with Sj\u00f6gren\u2019s disease (TWINSS): week 24 results of a randomised, double-blind, placebo-controlled, phase 2b dose-ranging study","volume":"404","author":"Fisher","year":"2024","journal-title":"The Lancet"},{"key":"2025090313283870000_10.4.e004914.12","doi-asserted-by":"crossref","first-page":"1583","DOI":"10.1038\/s41591-024-03009-3","article-title":"CD40 ligand antagonist dazodalibep in Sj\u00f6gren\u2019s disease: a randomized, double-blinded, placebo-controlled, phase 2 trial","volume":"30","author":"St. Clair","year":"2024","journal-title":"Nat Med"},{"key":"2025090313283870000_10.4.e004914.13","doi-asserted-by":"publisher","DOI":"10.1136\/ard.2010.143743"},{"key":"2025090313283870000_10.4.e004914.14","doi-asserted-by":"publisher","DOI":"10.1111\/j.1600-0447.1983.tb09716.x"},{"key":"2025090313283870000_10.4.e004914.15","doi-asserted-by":"publisher","DOI":"10.1093\/rheumatology\/keq240"},{"key":"2025090313283870000_10.4.e004914.16","first-page":"22","article-title":"EULAR Sj\u00f6gren\u2019s syndrome disease activity index (ESSDAI): a user guide","volume":"1","author":"Seror","year":"2015","journal-title":"RMD Open [Internet]"},{"key":"2025090313283870000_10.4.e004914.17","doi-asserted-by":"publisher","DOI":"10.1136\/ard-2023-224503"},{"key":"2025090313283870000_10.4.e004914.18","doi-asserted-by":"publisher","DOI":"10.1093\/rheumatology\/keh407"},{"key":"2025090313283870000_10.4.e004914.19","doi-asserted-by":"crossref","unstructured":"Wang H , Liu M . Complement C4, Infections, and Autoimmune Diseases. Front Immunol 2021;12. doi:10.3389\/fimmu.2021.694928","DOI":"10.3389\/fimmu.2021.694928"},{"key":"2025090313283870000_10.4.e004914.20","doi-asserted-by":"crossref","first-page":"37","DOI":"10.2147\/NDT.S151238","article-title":"Plasma complement component 4 increases in patients with major depressive disorder","volume":"14","author":"Wei","year":"2018","journal-title":"Neuropsychiatr Dis Treat"},{"key":"2025090313283870000_10.4.e004914.21","doi-asserted-by":"crossref","first-page":"701","DOI":"10.1200\/JCO.20.03375","article-title":"Benefits of Digital Symptom Monitoring With Patient-Reported Outcomes During Adjuvant Cancer Treatment","volume":"39","author":"Basch","year":"2021","journal-title":"J Clin Oncol"},{"key":"2025090313283870000_10.4.e004914.22","first-page":"4370","volume-title":"A Narrative Review on the Collection and Use of Electronic Patient\u2010Reported Outcomes in Cancer Survivorship Care with Emphasis on Symptom Monitoring","volume":"29","author":"Hurk","year":"2022"},{"key":"2025090313283870000_10.4.e004914.23","first-page":"283","article-title":"P284\u2003Evaluation of a self-management smartphone app for those living with Sj\u00f6gren\u2019s syndrome: a fully remote randomised pilot and feasibility trial","volume":"61","author":"McCallum","year":"2022","journal-title":"Rheumatology (Sunnyvale)"},{"key":"2025090313283870000_10.4.e004914.24","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2020-eular.138"}],"container-title":["RMD Open"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1136\/rmdopen-2024-004914","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,9,3]],"date-time":"2025-09-03T20:28:51Z","timestamp":1756931331000},"score":1,"resource":{"primary":{"URL":"https:\/\/rmdopen.bmj.com\/lookup\/doi\/10.1136\/rmdopen-2024-004914"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,11]]},"references-count":24,"journal-issue":{"issue":"4","published-online":{"date-parts":[[2024,11,24]]},"published-print":{"date-parts":[[2024,11]]}},"alternative-id":["10.1136\/rmdopen-2024-004914"],"URL":"https:\/\/doi.org\/10.1136\/rmdopen-2024-004914","relation":{},"ISSN":["2056-5933"],"issn-type":[{"value":"2056-5933","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,11]]}}}